Skip to main content
Erschienen in: Somnologie 2/2023

Open Access 18.02.2023 | Original Studies

Use of drug-induced sleep endoscopy in Germany—an analysis based on claims data

verfasst von: M. Braun, B. A. Stuck, C. Schöbel, A. Steffen

Erschienen in: Somnologie | Ausgabe 2/2023



Drug-induced sleep endoscopy (DISE) has recently gained relevance as a diagnostic tool for obstructive sleep apnea (OSA). However, it is unclear to what extent and in which patient cohorts DISE is used in Germany. With introduction of specific coding for this method in 2021 (Operationen- und Prozedurenschluessel, OPS code), usage can now be analyzed based on diagnosis-related groups (DRG) claims data.


Aggregated data from all inpatient DISE procedures conducted in German hospitals in 2021 were obtained from the publicly available Institut fuer das Entgeltsystem im Krankenhaus (InEK) database. Patient-relevant information as well as data on hospitals providing the examinations were exported and analyzed.


Between January and December 2021, a total of 2765 DISE procedures were conducted and documented using the newly introduced specific code (1-611.01). Most patients were male (75.6%), in the age categories 30–39 (15.2%) and 40–49 years (17.2%), and presented with the lowest patient clinical complexity level (PCCL; class 0 = 81.88%). Pediatric use was rare (1.8%). Leading main diagnoses of patients were G47.31 (OSA) and J34.2 (deviation of nasal septum). The most common procedures conducted together with DISE were nasal surgery, and the examination was mostly provided in large public hospitals with more than 800 beds.


Though the OSA prevalence in Germany is high, use of DISE as a diagnostic tool is low and represented only 4.4% of cases with a main diagnosis of OSA in 2021. Since specific coding was only introduced in January 2021, trends cannot yet be identified. Noticeable is the frequent combination of DISE with nasal surgery, which is not obviously related to a diagnosis of OSA. Limitations of the study are mainly related to the underlying data, which are available for the inpatient sector only, and due to potentially limited use of the OPS code, which was introduced recently and might not be known to all hospitals.
Scan QR code & read article online
Obstructive sleep apnea (OSA) is a well-recognized disorder that can lead to several significant and potentially life-threatening sequelae such as excessive daytime sleepiness, with a higher risk of motor vehicle collisions or cardiovascular diseases [1, 2]. Continuous positive airway pressure and its variants (PAP) are often regarded as first-line treatment for OSA; however, long-term adherence to this treatment is often suboptimal [3]. Therefore, a significant proportion of patients discontinue PAP and remain without sufficient therapy and thus exposed to the risk of OSA-related diseases. Many patients seek alternative treatment, including weight-reduction programs, mandibular advancement devices (MAD), or sleep surgery including hypoglossal nerve stimulation (HNS). For the latter and for pharyngeal surgery, drug-induced sleep endoscopy (DISE) is recognized as a diagnostic tool to identify collapse patterns that are considered as exclusion criteria or risk factors for suboptimal outcomes [47]. Consensus recommendations and guidelines for the indication, recommended maneuvers during the examination, and structured evaluation techniques have been established previously [8]. Despite this and its increasing use, DISE was conducted without specific procedural coding in German hospitals until recently.
Based on the International Classification of Procedures in Medicine, which was published by the World Health Organization in 1978, a German modification was introduced in 1994 to allow documentation of diagnostic and therapeutic measures conducted in the German healthcare system (Operationen- und Prozedurenschluessel, OPS) [9]. The classification is managed by the German Institute for Medical Documentation and Information (DIMDI), which was merged with the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) in 2020 and is updated annually to integrate new methods into the nomenclature. Today, the OPS classification consists of six chapters with more than 230 procedure classes and approximately 19,000 different procedures. This granularity allows procedures to be described in detail, which is required for differentiated reimbursement based on diagnosis-related groups (DRG). In addition, OPS codes are an important source of data for statistical analysis of healthcare services conducted in the German inpatient sector.
For integration of new OPS codes, a specific process was established in which scientific societies, hospitals, federations, and other healthcare institutions can submit an application for modification of an existing code or implementation of a new code [10].
While DISE is used for advanced diagnostics in patients with OSA in many clinics in Germany, a specific OPS code for this procedure was not previously available. To enable specific coding, the working group Sleep Medicine within the German Society of Otorhinolaryngology, Head and Neck Surgery, applied for implementation of a specific code for DISE in January 2020. The application was accepted in July 2020 and a new OPS code “1-611.01 Upper Airway Endoscopy—with flexible endoscope under sedation (sleep endoscopy)” was defined and introduced with the 2021 update of the OPS catalogue [11]. Since DISE is not listed in the German catalogue of outpatient reimbursement (Einheitlicher Bewertungsmaßstab, EBM), this examination is only reimbursed by statutory health insurances in hospitals. For patients with private insurance, DISE is usually reimbursed in the outpatient sector as well as in hospitals. To ensure continuous reimbursement and access for all patients, a specific OPS code is thus considered important, as it can also be relevant for further development of DRG-based payments.

Study objectives

Though DISE is established in the diagnostic management of OSA patients seeking alternative treatment options, no data exist on its actual use in routine clinical practice in Germany. The objective of this study is to analyze the use of this diagnostic tool in the German hospital sector, which is now possible with the introduction of the new OPS code.

Materials and methods


Claims data from all patients receiving inpatient diagnostic or therapeutic services in German hospitals can be accessed via the website of the German Institute for the Hospital Remuneration System (Institut fuer das Entgeltsystem im Krankenhaus, InEK) [12]. Data are updated three times per year, which allows analysis of the use of healthcare services close to the time of consumption and thus description of a quite recent picture of the actual situation. The dataset obtained for this analysis consisted of demographic information, procedural information, main diagnosis, patient clinical complexity levels (PCCL), and comorbidities, as well as the type of hospital that provided the examination. Data were retrieved for the complete year 2021 on all patients who received a DISE in that period. Additionally, data were obtained for all cases admitted in 2021 with a main diagnosis of OSA, which were identified using the ICD-10 code G47.31 (International Classification of Diseases, German modification, version 10). To account for privacy regulations, aggregated patient data only are available and data are thus reported in categories.

Statistical analysis

Data were managed using SPSS software (IBM, Armonk, NY, USA, version 26.0). Data items for SARS-CoV 2‑related tests, which were mandatory for hospital admissions during the period evaluated, were excluded from the set, since those were considered nonrelevant for the research question. Standard statistical techniques were used to describe the populations and chi2 tests were applied to determine variances between groups.


In the period from January until December 2021, 2765 procedures were conducted with the DISE-specific OPS code in German hospitals. Most patients were male (75.6%) and in the age groups 30–39 years (15.2%), 40–49 years (17.2%), and 54–59 years (15.2%). The most common diagnoses leading to admission for DISE were obstructive sleep apnea (G47.31, 46.3%) or deviation of the nasal septum (J43.2, 15.1%; Table 1). DISE was often combined with additional procedures during the same hospital stay (Table 2). Of these, nasal surgery (18.1%), other endoscopic examinations, or polysomnography (12.0%) were most often performed during the same admission (Table 2). Implantation of a hypoglossal nerve stimulator (HNS), which requires DISE before treatment to confirm eligibility, was carried out in only 16 patients during the same admission, while 356 cases were performed in 2021. Most DISE examinations for HNS are thus conducted independently of the implantation procedure, during a separate hospital stay or at an outpatient visit. The mean length of hospital stay among all patients receiving DISE was 4.3 ± 10.9 days, while one third (34.9%) had a stay of 1.0 day, which was categorized as a short-term admission.
Table 1
Main diagnoses and comorbidities of patients undergoing drug-induced sleep endoscopy (DISE) in Germany (Jan-Dec 2021, DISE admissions: n = 2765)
% of all cases
Top 5 main diagnoses in cases where DISE was performed
ICD 10 code
Obstructive sleep apnea
Deviated nasal septum
Hypertrophy of nasal turbinates
Mouth breathing
Other diseases of pharynx
Top 5 comorbidities in cases where DISE was performed
ICD 10 code
Hypertrophy of nasal turbinates
Obstructive sleep apnea
Essential (primary) hypertension
Deviated nasal septum
Mouth breathing
Table 2
Other procedures carried out in patients admitted to hospital for drug-induced sleep endoscopy (DISE) in Germany (Jan-Dec 2021, DISE admissions: n = 2765)
OPS code
% of all cases
Diagnostic laryngoscopy
Surgery on inferior turbinates: lateralization
Diagnostic pharyngoscopy, direct
Submucosal resection and plastic reconstruction of the nasal septum: plastic correction with resection
Surgery on inferior turbinates: destruction with diathermy
Diagnostic esophagoscopy
Monitoring of respiration, heart, and circulation without measuring pulmonary artery pressure and central venous pressure
Diagnostic rhinoscopy
Diagnostic pharyngoscopy, direct, other techniques
Patients receiving DISE often presented with comorbidities (Table 1). Commonly found were diseases of the nose and paranasal sinuses (52.9%), arterial hypertension (29.4%), obesity (14.4%), or diabetes type II (6.6%).

Comparison to patients hospitalized for OSA

During the same time period as included in the analysis, a total of 60,451 patients were admitted to German hospitals for OSA-related diagnostic or therapeutic measures (Table 3). The length of stay in these patients was shorter than for DISE admissions, with a mean of 1.8 ± 1.5 days and 37.7% short-term admissions.
Table 3
Diagnostic procedures carried out in patients admitted to hospital with main diagnosis of obstructive sleep apnea (OSA; G47.31) in Germany (Jan-Dec 2021, OSA admissions: n = 60,451)
OPS code
% of all cases
Plethysmography (whole body)
Measurement of CO lung diffusion capacity
Cardiorespiratory polygraphy
Multiple sleep latency test (MSLT)/maintenance of wakefulness test (MWT)
Measurement of functional residual capacity (FRC)
Drug-induced sleep endoscopya
Psychosomatic and psychotherapeutic diagnostic
Six-minute walk test
aMissing cases to total DISE admissions were coded with different main diagnoses (see Table 1)
The cohort of patients admitted for DISE differed in various aspects to those hospitalized for OSA in general. As such, patients with OSA in general had a different age distribution (Fig. 1) and were more often of female gender (30.3 vs. 24.4%, p < 0.001). Additionally, patients hospitalized for OSA in general were significantly less healthy, which is represented by higher PCCL scores (Table 4). Patients undergoing DISE presented significantly less often with comorbid conditions such as arterial hypertension (29.4 vs. 37.2%, p < 0.001), coronary artery disease (3.4 vs. 5.6%, p < 0.001), congestive heart failure (1.5 vs. 2.3%, p= 0.003), or type II diabetes (6.6 vs. 11.2%, p < 0.001) than patients admitted for OSA in general. Obesity was significantly more prevalent in the general group of OSA patients (14.4 vs. 32.5%, p < 0.001). Among those with OSA and obesity, 17.5% had a body mass index (BMI) of > 35 kg/m2 and 8.4% were highly obese, with a BMI > 40 kg/m2, compared to 4.9 and 1.4% of cases, respectively, in the DISE cohort (Fig. 2).
Table 4
Characteristics of patients admitted for DISE compared to all patients admitted with a main diagnosis of OSA
DISE admissions (%)
All OSA admissions (%)
Gender (m/w, %)
< 0.001
Obesity (WHO grade ≥ 1)
< 0.001
Arterial hypertension
< 0.001
Coronary heart disease
< 0.001
Congestive heart failure
Diabetes mellitus type II
< 0.001
Patient comorbidity and complications level
PCCL class 0
PCCL class 1
PCCL class 2
< 0.001
PCCL class 3
< 0.001
PCCL class 4
< 0.001
PCCL class 5
< 0.001
PCCL class 6
< 0.001
DISE drug-induced sleep endoscopy, OSA obstructive sleep apnea, WHO World Health Organization, PCCL patient clinical complexity level
While in theory, DISE can be conducted at any hospital in Germany with a specialist trained in this technique, the examination is disproportionately provided across hospitals (Fig. 3). While large institutions with more than 800 beds admitted only 25.3% of all OSA patients, they conducted 52.6% of all DISE procedures. On the other hand, hospitals with less than 200 beds conducted only 6.1% of all DISE procedures in the period analyzed, while they provided care for 19.7% of all OSA cases.


The clinical value of DISE has been proven in multiple trials and it is recommended as a diagnostic tool in patients with OSA seeking PAP alternatives, especially in screening for MAD and HNS or for planning of surgical interventions on the upper airway [13, 14]. As expected, the examination is used in Germany, but in the absence of a specific procedure code, it was not possible to estimate the actual use until now. This study provides a first analysis of routine clinical practice in German hospitals, and presents some interesting findings.
Although DISE was introduced many years ago, its relevance as a diagnostic tool for patients with OSA in Germany is limited. In 2021, only 2765 examinations were conducted in the hospital sector, which represents 4.5% of all admissions for OSA. Other countries that use DISE in routine clinical practice report remarkably higher use. A recent analysis from the Netherlands, for example, stated 7090 examinations in 2018, while this country has only a fifth of the German population [15].
With most cases performed by hospitals with more than 800 beds, DISE is a method that is largely provided by clinics with a higher level of specialization. Though no data are available on the medical discipline that conducts the examination, it is likely that these will be mainly larger otorhinolaryngology or pneumological departments that specialize in advanced diagnosis and treatment of OSA. As interpretation of DISE findings and subsequent therapeutic decision-making requires training and experience, it seems reasonable that this examination is mainly provided by specialized centers with higher caseloads.
Patients receiving DISE are often admitted for a combination of examinations or interventions. Interestingly, 15% of patients receiving DISE were admitted with a main diagnosis of nasal septum deviation and 18% received DISE in combination with some type of nasal surgery. Though it does not seem logical to admit a patient with such a diagnosis for DISE, which is not obviously linked to OSA, there are a few reasons that could explain the high number of patients with nasal main diagnoses undergoing DISE. First, snoring is one of the leading symptoms in OSA and patients might be admitted with this diagnosis before OSA is confirmed, i.e., in a hospital stay that combines polysomnography and DISE. Secondly, as DISE is conducted largely by otorhinolaryngologists, concurrent septal deviation or other nasal conditions that require treatment are performed in the same hospital stay and under the same general anesthesia as the DISE to reduce the burden for the patient and streamline the treatment process. Conducting DISE at the same time as other surgeries also explains the relatively long mean hospital stay of 4.3 days, which would not be required for DISE alone. With its low invasiveness, the examination is commonly carried out as an outpatient procedure in other healthcare systems [8]. Due to limitations to reimbursement within the German statutory health insurance system, this is possible only in private or self-paying patients, and those cases are not documented in any statistic. With introduction of the specific OPS code, reimbursement of DISE is now possible in hospitals via DRG payments. Given constant budget constraints, it remains to be seen whether the new code will lead to improved funding of this examination technique. Based on anecdotal feedback from some clinics providing DISE, payers often deny claims ex-post, even if proper coding was used and the procedure was conducted per standards of care.
The population receiving DISE consists largely of male patients of the typical age groups in which symptoms become apparent. Although patients present with the typical comorbidities, they tend to be rather healthy, with only few classified as more complex in the respective higher PCCL groups. As such, the population receiving DISE can be considered healthier when compared to the general population admitted for OSA. This is supported by the significantly higher rates of all comorbidities investigated in the population of all admitted OSA patients.
Of particular interest is the distribution of obesity levels across the two groups: patients with higher levels of obesity are underrepresented among patients receiving DISE. Given that accumulation of fat tissue in the upper airway can lead to more complex anatomical situations, it is surprising that DISE is not used more often in this population, since it could lead to improved understanding of the pathophysiology and thus better decision-making. Specific reasons cannot be derived from the available data, as the particular indication for the examination and the phase of the patient in their disease journey is not documented. Potentially, DISE is mainly used in patients who undergo screening for treatments that have specific BMI limits, such as MAD or HNS therapy. Another explanation could be that DISE is mainly used in cases with low adherence to PAP therapy to evaluate potential second-line treatments, which is more common in patients with lower levels of obesity [16]. Additionally, use of DISE will certainly be influenced by individual patient preferences, daytime symptoms, and treatment motivation. Given the fact that this examination is mainly provided by larger hospitals, accessibility across the country will likely also drive demand from patients.


This study is subject to certain limitations, which are mainly related to the dataset that was available for analysis. First, the specific OPS code was only implemented in the analyzed year. Some providers might not have been aware that DISE can be documented with this code and some cases could have been performed using the nonspecific coding that was available beforehand. Second, the study only includes DISE cases performed during a hospital admission that led to billing of a DRG. Hospitals with specific agreements for ambulatory care or which use other reimbursement schemes could not be obliged to use the new code. Since DISE is also offered by physicians in the outpatient sector for privately insured or self-paying patients, these cases are also not included, as there is no requirement to report them. As such, there could be an underreporting of the actual DISE cases performed in 2021. As reimbursement of DISE by statutory insurance is only available for hospitals and these payers covers 88% of the German population, we believe, however, that the dataset covers the vast majority of examinations [17]. Another limitation is the completeness of the dataset itself, which provides information at only an aggregated level and in limited granularity; therefore, a more advanced analysis including patient pathways and disease journeys was not possible. This would, however, be interesting to further evaluate this technique for diagnosis of patients with OSA.


With introduction of specific coding for DISE in Germany, it is now possible to analyze its use based on DRG claims data. This article provides first insights into the role of this examination technique as a diagnostic tool in OSA patients and the cohort receiving DISE in German hospitals. The relevance of this tool in the diagnostic workup of these patients is relatively low, however, compared to the prevalence of the disease. Although this is only a first analysis, it can be concluded that patients receiving DISE are younger, less obese, and present with fewer comorbid conditions. Given that PAP alternatives are not only required in this cohort, these findings may be relevant, since they might lead to improved access to DISE, so that more patients can receive this examination in a work-up for advanced diagnosis of OSA and potential second-line treatments.


Conflict of interest

M. Braun is an employee of Onera Health (Eindhoven, the Netherlands). B. A. Stuck has received research grants, reimbursement of travel expenses, and speaking fees from Neuwirth Medical Products, XM Consult, Itamar Medical, and Inspire Medical Systems Inc. His department has received financial support for meetings or symposia from Neuwirth Medical Products and Inspire Medical Systems Inc., and he serves as a consultant for Itamar Medical. A. Steffen is a consultant for Inspire Medical Systems Inc. and for ZOLL Respicardia Inc. C. Schöbel declares no conflicting interests.
Ethics committee approval was not required for this study. For this article, no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Unsere Produktempfehlungen



  • Aktuelles, gesichertes Fachwissen zu Ätiologie, Pathophysiologie, Differentialdiagnostik und Therapie von Schlafstörungen

• Multidisziplinärer Ansatz

e.Med Interdisziplinär


Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Jetzt bestellen und 100 € sparen!

e.Dent – Das Online-Abo der Zahnmedizin


Mit e.Dent erhalten Sie Zugang zu allen zahnmedizinischen Fortbildungen und unseren zahnmedizinischen und ausgesuchten medizinischen Zeitschriften.

Weitere Produktempfehlungen anzeigen
Zurück zum Zitat Stuck BA et al (2020) Teil-Aktualisierung S3-Leitlinie Schlafbezogene Atmungsstörungen bei Erwachsenen. AWMFCrossRef Stuck BA et al (2020) Teil-Aktualisierung S3-Leitlinie Schlafbezogene Atmungsstörungen bei Erwachsenen. AWMFCrossRef
Use of drug-induced sleep endoscopy in Germany—an analysis based on claims data
verfasst von
M. Braun
B. A. Stuck
C. Schöbel
A. Steffen
Springer Medizin
Erschienen in
Somnologie / Ausgabe 2/2023
Print ISSN: 1432-9123
Elektronische ISSN: 1439-054X

Weitere Artikel der Ausgabe 2/2023

Somnologie 2/2023 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Weniger aneurysmenbedingte Subarachnoidalblutungen unter fünf Arzneien

Lisinopril, Amlodipin, Simvastatin, Metformin und Tamsulosin – unter diesen fünf Medikamenten ist das Risiko für Subarachnoidalblutungen durch Aneurysmen deutlich reduziert. Sie könnten sich möglicherweise zur Prävention solcher Blutungen eignen.

Myasthenia gravis durch Krebsimmuntherapie

13.06.2024 Myasthenia gravis Nachrichten

Sie sind sehr selten, können aber schwerwiegende Folgen haben: immunologische Nebenwirkungen unter Checkpointhemmern. Ein Behandlungsteam berichtet nun über einen Mann, der während einer Darmkrebsbehandlung eine Myasthenia gravis entwickelt.

Auch nach schwerem Schlaganfall lohnt sich frühe Antikoagulation

06.06.2024 Apoplex Nachrichten

Personen mit Vorhofflimmern haben nach einem schweren ischämischen Schlaganfall keine Nachteile, wenn sie etwas früher als empfohlen eine orale Antikoagulation erhalten. Tendenziell kommt es dann sogar seltener zu vaskulären Ereignissen.

Alice-im-Wunderland-Syndrom gehäuft bei Migräne mit Aura

06.06.2024 Migräne Nachrichten

Eine verzerrte Wahrnehmung von Raum, Zeit oder Körper tritt vor allem bei Migräne mit Aura auf: 20% dieser Migränekranken haben solche Veränderungen schon einmal erlebt, meist während einer Migräne-Attacke. Möglicherweise handelt es sich hier um eine Aura-Variante.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.